ATE195123T1 - Pyrazolderivate und verfahren zu deren herstellung - Google Patents

Pyrazolderivate und verfahren zu deren herstellung

Info

Publication number: ATE195123T1
Authority: AT; Austria
Prior art keywords: pct; date oct; production; sec; formula
Prior art date: 1995-04-03

Application number

AT96909115T

Other languages

English (en)

Inventor

Peter Traxler

Pascal Furet

Guido Bold

Joerg Frei

Marc Lang

Original Assignee

Novartis Erfind Verwalt Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-03

Filing date

1996-03-22

Publication date

2000-08-15

1996-03-22 Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh

2000-08-15 Application granted granted Critical

2000-08-15 Publication of ATE195123T1 publication Critical patent/ATE195123T1/de

Links

238000004519 manufacturing process Methods 0.000 title abstract 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
101800003838 Epidermal growth factor Proteins 0.000 abstract 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229940116977 epidermal growth factor Drugs 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT96909115T 1995-04-03 1996-03-22 Pyrazolderivate und verfahren zu deren herstellung ATE195123T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CH93795		1995-04-03
CH42196		1996-02-16
PCT/EP1996/001263 WO1996031510A1 (en)	1995-04-03	1996-03-22	Pyrazole derivatives and processes for the preparation thereof

Publications (1)

Publication Number	Publication Date
ATE195123T1 true ATE195123T1 (de)	2000-08-15

Family

ID=25684532

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96909115T ATE195123T1 (de)	1995-04-03	1996-03-22	Pyrazolderivate und verfahren zu deren herstellung

Country Status (13)

Country	Link
US (1)	US5981533A (de)
EP (1)	EP0819129B1 (de)
JP (1)	JP4249804B2 (de)
AT (1)	ATE195123T1 (de)
AU (1)	AU711592B2 (de)
CA (1)	CA2214086C (de)
DE (1)	DE69609602T2 (de)
DK (1)	DK0819129T3 (de)
ES (1)	ES2150113T3 (de)
GR (1)	GR3034415T3 (de)
NZ (1)	NZ304859A (de)
PT (1)	PT819129E (de)
WO (1)	WO1996031510A1 (de)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW321649B (de) *	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en) *	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
GB9508537D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9508538D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9508535D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivative
GB9508565D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quiazoline derivative
EP0824525B1 (de) *	1995-04-27	2001-06-13	AstraZeneca AB	Chinazolin derivate
ATE212993T1 (de) *	1995-07-06	2002-02-15	Novartis Erfind Verwalt Gmbh	Pyrolopyrimidine und verfahren zu ihrer herstellung
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
US6140317A (en) *	1996-01-23	2000-10-31	Novartis Ag	Pyrrolopyrimidines and processes for their preparation
JP4471404B2 (ja)	1996-02-13	2010-06-02	アストラゼネカユーケイリミテッド	Ｖｅｇｆインヒビターとしてのキナゾリン誘導体
GB9603097D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline compounds
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
ATE211134T1 (de)	1996-03-05	2002-01-15		4-anilinochinazolin derivate
GB9607729D0 (en) *	1996-04-13	1996-06-19	Zeneca Ltd	Quinazoline derivatives
DE69738468T2 (de)	1996-08-23	2009-01-08	Novartis Ag	Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
WO1998014449A1 (en) *	1996-10-02	1998-04-09	Novartis Ag	Fused pyrazole derivatives and processes for their preparation
ID18494A (id) *	1996-10-02	1998-04-16	Novartis Ag	Turunan pirazola leburan dan proses pembuatannya
WO1998014450A1 (en) *	1996-10-02	1998-04-09	Novartis Ag	Pyrimidine derivatives and processes for the preparation thereof
CN1237177A (zh)	1996-11-27	1999-12-01	辉瑞大药厂	稠合的二环嘧啶衍生物
CN1278724A (zh)	1997-10-06	2001-01-03	巴斯福股份公司	抑制酪氨酸激酶活性的茚并[1,2－c]吡唑衍生物
PT1023063E (pt) *	1997-10-06	2004-02-27	Abbott Gmbh & Co Kg	Derivados de indeno¬1,2-c\|- nafto¬1,2-c\|- e benzo¬6,7\|ciclo-hepta¬1,2-c\|pirazole
ES2356886T3 (es)	1998-03-31	2011-04-14	Kyowa Hakko Kirin Co., Ltd.	Compuestos heterocíclicos nitrogenados.
IL148718A0 (en) *	1999-09-17	2002-09-12	Abbott Gmbh & Co Kg	Pyrazolopyrimidines as therapeutic agents
US7071199B1 (en)	1999-09-17	2006-07-04	Abbott Gmbh & Cco. Kg	Kinase inhibitors as therapeutic agents
PL203782B1 (pl)	1999-11-05	2009-11-30	Astrazeneca Ab	Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
WO2003029209A2 (en) *	2001-10-02	2003-04-10	Smithkline Beecham Corporation	Chemical compounds
DE10294485T5 (de)	2001-10-29	2004-04-29	DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung	Mit Mnk-Kinase homologe Proteine, die in die Regulation der Energiehomöostase und den Organellenmetabolismus involviert sind
EP1530573B1 (de) *	2002-07-25	2008-03-19	Pfizer Italia S.r.l.	Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren
US20040121407A1 (en) *	2002-09-06	2004-06-24	Elixir Pharmaceuticals, Inc.	Regulation of the growth hormone/IGF-1 axis
EP1638966B1 (de) *	2003-05-28	2008-03-19	Universita Degli Studi Di Siena	4-substituierte derivate von pyrazolo¬3,4-d pyrimidin und deren verwendungen
US7429596B2 (en) *	2003-06-20	2008-09-30	The Regents Of The University Of California	1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
DE10356579A1 (de) *	2003-12-04	2005-07-07	Merck Patent Gmbh	Aminderivate
KR20070085340A (ko) *	2004-10-12	2007-08-27	디코드 제네틱스, 아이엔씨.	폐쇄성 동맥 질환용의 아릴 설폰아미드 주변 치환된바이사이클릭 화합물
US9512125B2 (en)	2004-11-19	2016-12-06	The Regents Of The University Of California	Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
WO2006064196A1 (en)	2004-12-14	2006-06-22	Astrazeneca Ab	Pyrazolopyrimidine compounds as antitumor agents
US7915410B2 (en) *	2005-09-09	2011-03-29	Bristol-Myers Squibb Company	Acyclic IKur inhibitors
CN101454325A (zh)	2006-03-09	2009-06-10	法马科皮亚公司	用于治疗代谢性疾病的8-杂芳基嘌呤mnk2抑制剂
KR101499783B1 (ko) *	2006-04-04	2015-03-09	더 리젠트스 오브 더 유니이버시티 오브 캘리포니아	키나제 길항물질
US20110160232A1 (en)	2007-10-04	2011-06-30	Pingda Ren	Certain chemical entities and therapeutic uses thereof
AU2009204483B2 (en)	2008-01-04	2014-03-13	Intellikine, Llc	Certain chemical entities, compositions and methods
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5547099B2 (ja)	2008-03-14	2014-07-09	インテリカイン，エルエルシー	キナーゼ阻害剤および使用方法
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
US20110224223A1 (en)	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
MX2011000216A (es)	2008-07-08	2011-03-29	Intellikine Inc	Inhibidores de cinasa y metodos para su uso.
WO2010036380A1 (en)	2008-09-26	2010-04-01	Intellikine, Inc.	Heterocyclic kinase inhibitors
WO2010045542A2 (en)	2008-10-16	2010-04-22	The Regents Of The University Of California	Fused ring heteroaryl kinase inhibitors
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
MX2011004824A (es)	2008-11-07	2012-01-12	Triact Therapeutics Inc	Uso de derivados de butano catecólico en terapia contra el cáncer.
EP2400985A2 (de)	2009-02-25	2012-01-04	OSI Pharmaceuticals, LLC	Kombination eines anti-igf-1r-antikörpers oder eines igf-bindungsproteins und eines kleinmoleküligen igf-1r-kinase-inhibitors
JP2012519170A (ja)	2009-02-26	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja)	2009-02-27	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
EP2401614A1 (de)	2009-02-27	2012-01-04	OSI Pharmaceuticals, LLC	Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
EP2408479A1 (de)	2009-03-18	2012-01-25	OSI Pharmaceuticals, LLC	Kombinationskrebstherapie mit verabreichung eines egfr-hemmers und eines igf-1r-hemmers
WO2010129816A2 (en)	2009-05-07	2010-11-11	Intellikine, Inc.	Heterocyclic compounds and uses thereof
GEP201706639B (en)	2009-08-17	2017-03-27	Intellikine Llc	Heterocyclic compounds and uses thereof
WO2011047384A2 (en)	2009-10-16	2011-04-21	The Regents Of The University Of California	Methods of inhibiting ire1
JP2013510564A (ja)	2009-11-13	2013-03-28	パンガエアビオテック、ソシエダッド、リミターダ	肺癌におけるチロシンキナーゼ阻害剤に対する応答を予測するための分子バイオマーカー
JP5951600B2 (ja)	2010-05-21	2016-07-13	インフィニティーファーマシューティカルズ，インコーポレイテッド	キナーゼ調節のための、化合物、組成物および方法
US8901133B2 (en)	2010-11-10	2014-12-02	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP2468883A1 (de)	2010-12-22	2012-06-27	Pangaea Biotech S.L.	Molekulare Biomarker zur Vorhersage der Reaktion auf Tyrosinkinaseinhibitoren bei Lungenkrebs
KR20180080358A (ko)	2011-01-10	2018-07-11	인피니티 파마슈티칼스, 인코포레이티드	이소퀴놀린온 및 이의 고체 형태의 제조 방법
US9134297B2 (en)	2011-01-11	2015-09-15	Icahn School Of Medicine At Mount Sinai	Method and compositions for treating cancer and related methods
EP2492688A1 (de)	2011-02-23	2012-08-29	Pangaea Biotech, S.A.	Molekulare Biomarker zur Vorhersage der Reaktion auf die Antitumorbehandlung bei Lungenkrebs
JP6130305B2 (ja)	2011-02-23	2017-05-17	インテリカイン，エルエルシー	キナーゼ阻害剤の組み合わせおよびそれらの使用
WO2012129145A1 (en)	2011-03-18	2012-09-27	OSI Pharmaceuticals, LLC	Nscle combination therapy
US9896730B2 (en)	2011-04-25	2018-02-20	OSI Pharmaceuticals, LLC	Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
EP2734530A1 (de)	2011-07-19	2014-05-28	Infinity Pharmaceuticals, Inc.	Heterocyclische verbindungen und ihre verwendung
CN103930422A (zh)	2011-07-19	2014-07-16	无限药品股份有限公司	杂环化合物及其用途
CN103998442B (zh)	2011-08-29	2016-09-14	无限药品股份有限公司	杂环化合物及其用途
WO2013033380A1 (en)	2011-08-31	2013-03-07	Genentech, Inc.	Diagnostic markers
MX370814B (es)	2011-09-02	2020-01-08	Univ California	Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US20130084287A1 (en)	2011-09-30	2013-04-04	Genentech, Inc.	Diagnostic markers
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2013190089A1 (en)	2012-06-21	2013-12-27	Pangaea Biotech, S.L.	Molecular biomarkers for predicting outcome in lung cancer
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014052669A1 (en)	2012-09-26	2014-04-03	The Regents Of The University Of California	Modulation of ire1
IL291945B2 (en)	2012-11-01	2025-11-01	Infinity Pharmaceuticals Inc	Treatment of cancers using pi3 kinase isoform modulators
GB201223308D0 (en)	2012-12-21	2013-02-06	Univ Sunderland	Enzyme inhibitors
US9834575B2 (en)	2013-02-26	2017-12-05	Triact Therapeutics, Inc.	Cancer therapy
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014147246A1 (en)	2013-03-21	2014-09-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
WO2014153509A1 (en)	2013-03-22	2014-09-25	Millennium Pharmaceuticals, Inc.	Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
CA2923667A1 (en)	2013-09-09	2015-03-12	Triact Therapeutics, Inc.	Cancer therapy
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
MX389256B (es)	2013-10-04	2025-03-20	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y usos de los mismos.
EP4066834A1 (de)	2014-03-19	2022-10-05	Infinity Pharmaceuticals, Inc.	Heterocyclische verbindungen zur verwendung in der behandlung von pi3k-gamma-vermittelten erkrankungen
WO2015156674A2 (en)	2014-04-10	2015-10-15	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
US20150320755A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
WO2016004272A1 (en) *	2014-07-02	2016-01-07	Pharmacyclics Llc	Inhibitors of bruton's tyrosine kinase
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP3237638B1 (de)	2014-12-24	2020-01-15	F.Hoffmann-La Roche Ag	Therapeutisches, diagnostisches und prognostisches verfahren für blasenkrebs
CN108349985A (zh)	2015-09-14	2018-07-31	无限药品股份有限公司	异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017184775A1 (en) *	2016-04-19	2017-10-26	The Regents Of The University Of California	Erbb inhibitors and uses thereof
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CA3028718A1 (en)	2016-06-24	2017-12-28	Infinity Pharmaceuticals, Inc.	Combination therapies
NZ754994A (en)	2016-12-22	2022-12-23	Amgen Inc	Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
ES2928576T3 (es)	2017-09-08	2022-11-21	Amgen Inc	Inhibidores de KRAS G12C y métodos de uso de los mismos
MA52501A (fr)	2018-05-04	2021-03-10	Amgen Inc	Inhibiteurs de kras g12c et leurs procédés d'utilisation
CA3099118A1 (en)	2018-05-04	2019-11-07	Amgen Inc.	Kras g12c inhibitors and methods of using the same
EP3790886B1 (de)	2018-05-10	2024-06-26	Amgen Inc.	Kras g12c-inhibitoren zur behandlung von krebs
US12324807B2 (en)	2018-06-01	2025-06-10	Cornell University	Combination therapy for PI3K-associated disease or disorder
EP3802535B1 (de)	2018-06-01	2022-12-14	Amgen, Inc	Kras-g12c-inhibitoren und verfahren zur verwendung davon
CA3099799A1 (en)	2018-06-11	2019-12-19	Amgen Inc.	Kras g12c inhibitors for treating cancer
MA51848A (fr)	2018-06-12	2021-04-21	Amgen Inc	Inhibiteurs de kras g12c et leurs procédés d'utilisation
AU2019352741A1 (en)	2018-10-04	2021-05-06	Assistance Publique-Hôpitaux De Paris (Aphp)	EGFR inhibitors for treating keratodermas
JP7516029B2 (ja)	2018-11-16	2024-07-16	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
US11053226B2 (en)	2018-11-19	2021-07-06	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MA54550A (fr)	2018-12-20	2022-03-30	Amgen Inc	Inhibiteurs de kif18a
MA54546A (fr)	2018-12-20	2022-03-30	Amgen Inc	Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
AU2019401495B2 (en)	2018-12-20	2025-06-26	Amgen Inc.	Heteroaryl amides useful as KIF18A inhibitors
EA202191730A1 (ru)	2018-12-20	2021-08-24	Эмджен Инк.	Ингибиторы kif18a
KR20210146287A (ko)	2019-03-01	2021-12-03	레볼루션 메디슨즈, 인크.	이환식 헤테로아릴 화합물 및 이의 용도
CN113727758A (zh)	2019-03-01	2021-11-30	锐新医药公司	双环杂环基化合物及其用途
EP3738593A1 (de)	2019-05-14	2020-11-18	Amgen, Inc	Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
EP3972973A1 (de)	2019-05-21	2022-03-30	Amgen Inc.	Festkörperformen
CN114391012B (zh)	2019-08-02	2025-10-31	美国安进公司	作为kif18a抑制剂的吡啶衍生物
JP7640521B2 (ja)	2019-08-02	2025-03-05	アムジエン・インコーポレーテツド	Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
ES3051918T3 (en)	2019-08-02	2025-12-30	Amgen Inc	Kif18a inhibitors
WO2021026098A1 (en)	2019-08-02	2021-02-11	Amgen Inc.	Kif18a inhibitors
EP4048671B1 (de)	2019-10-24	2026-03-18	Amgen Inc.	Pyridopyrimidinderivate als kras-g12c- und kras-g12d-inhibitoren zur behandlung von krebs
JP7823816B2 (ja)	2019-11-04	2026-03-04	レヴォリューション・メディスンズ，インコーポレイテッド	Ｒａｓ阻害剤
EP4054719B1 (de)	2019-11-04	2026-02-11	Revolution Medicines, Inc.	Ras-inhibitoren
KR20220109407A (ko)	2019-11-04	2022-08-04	레볼루션 메디슨즈, 인크.	Ras 억제제
BR112022008858A2 (pt)	2019-11-08	2022-09-06	Revolution Medicines Inc	Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
JP2023501528A (ja)	2019-11-14	2023-01-18	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の改善された合成
WO2021097207A1 (en)	2019-11-14	2021-05-20	Amgen Inc.	Improved synthesis of kras g12c inhibitor compound
WO2021108683A1 (en)	2019-11-27	2021-06-03	Revolution Medicines, Inc.	Covalent ras inhibitors and uses thereof
CN114929279A (zh)	2020-01-07	2022-08-19	锐新医药公司	Shp2抑制剂给药和治疗癌症的方法
CA3183032A1 (en)	2020-06-18	2021-12-23	Mallika Singh	Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
MX2023002248A (es)	2020-09-03	2023-05-16	Revolution Medicines Inc	Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
CR20230165A (es)	2020-09-15	2023-06-02	Revolution Medicines Inc	Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
CN117396472A (zh)	2020-12-22	2024-01-12	上海齐鲁锐格医药研发有限公司	Sos1抑制剂及其用途
IL308193A (en)	2021-05-05	2024-01-01	Revolution Medicines Inc	RAS inhibitors
CR20230558A (es)	2021-05-05	2024-01-24	Revolution Medicines Inc	Inhibidores de ras para el tratamiento del cáncer
WO2022235866A1 (en)	2021-05-05	2022-11-10	Revolution Medicines, Inc.	Covalent ras inhibitors and uses thereof
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
JP2025500878A (ja)	2021-12-17	2025-01-15	ジェンザイム・コーポレーション	Ｓｈｐ２阻害剤としてのピラゾロピラジン化合物
EP4227307A1 (de)	2022-02-11	2023-08-16	Genzyme Corporation	Pyrazolopyrazinverbindungen als shp2-inhibitoren
IL314883A (en)	2022-03-07	2024-10-01	Amgen Inc	A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
CN119136806A (zh)	2022-03-08	2024-12-13	锐新医药公司	用于治疗免疫难治性肺癌的方法
WO2023240263A1 (en)	2022-06-10	2023-12-14	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
PE20251879A1 (es)	2022-10-14	2025-07-22	Black Diamond Therapeutics Inc	Metodos de tratamiento del cancer usando derivados de isoquinolina o 6-aza-quinolina
AU2024241633A1 (en)	2023-03-30	2025-11-06	Revolution Medicines, Inc.	Compositions for inducing ras gtp hydrolysis and uses thereof
PE20260039A1 (es)	2023-04-07	2026-01-09	Revolution Medicines Inc	Inhibidores macrociclicos de ras
WO2024211663A1 (en)	2023-04-07	2024-10-10	Revolution Medicines, Inc.	Condensed macrocyclic compounds as ras inhibitors
TW202448897A (zh)	2023-04-14	2024-12-16	美商銳新醫藥公司	Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
CN121100123A (zh)	2023-04-14	2025-12-09	锐新医药公司	Ras抑制剂的结晶形式
WO2024229406A1 (en)	2023-05-04	2024-11-07	Revolution Medicines, Inc.	Combination therapy for a ras related disease or disorder
US20250049810A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
TW202530228A (zh)	2023-10-12	2025-08-01	美商銳新醫藥公司	Ｒａｓ抑制劑
TW202542151A (zh)	2023-12-22	2025-11-01	美商銳格醫藥有限公司	Ｓｏｓ１抑制劑及其用途
CN117865965B (zh) *	2024-01-08	2024-06-28	贵州省天然产物研究中心	吡咯并嘧啶-4-胺和吡唑并嘧啶-4-胺衍生物及制备方法和应用
WO2025171296A1 (en)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Ras inhibitors
TW202547461A (zh)	2024-05-17	2025-12-16	美商銳新醫藥公司	Ｒａｓ抑制劑
WO2025255438A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Ras inhibitors
WO2026015796A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015825A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015801A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026050446A1 (en)	2024-08-29	2026-03-05	Revolution Medicines, Inc.	Ras inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU658646B2 (en) *	1991-05-10	1995-04-27	Rhone-Poulenc Rorer International (Holdings) Inc.	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU661533B2 (en) *	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
IL112249A (en) *	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) *	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
EP0682027B1 (de) *	1994-05-03	1997-10-15	Novartis AG	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
CA2223081C (en) *	1995-06-07	2001-03-06	Pfizer Inc.	Heterocyclic ring-fused pyrimidine derivatives
WO1998014449A1 (en) *	1996-10-02	1998-04-09	Novartis Ag	Fused pyrazole derivatives and processes for their preparation
WO1998014450A1 (en) *	1996-10-02	1998-04-09	Novartis Ag	Pyrimidine derivatives and processes for the preparation thereof
EP0929645A1 (de) *	1996-10-04	1999-07-21	The Procter & Gamble Company	Verfahren zur herstellung einer waschmittelzusammensetzung mit niedrigem schüttgewicht durch prozess ohne turm

1996
- 1996-03-22 AU AU52733/96A patent/AU711592B2/en not_active Ceased
- 1996-03-22 EP EP96909115A patent/EP0819129B1/de not_active Expired - Lifetime
- 1996-03-22 PT PT96909115T patent/PT819129E/pt unknown
- 1996-03-22 US US08/930,904 patent/US5981533A/en not_active Expired - Lifetime
- 1996-03-22 ES ES96909115T patent/ES2150113T3/es not_active Expired - Lifetime
- 1996-03-22 DK DK96909115T patent/DK0819129T3/da active
- 1996-03-22 WO PCT/EP1996/001263 patent/WO1996031510A1/en not_active Ceased
- 1996-03-22 AT AT96909115T patent/ATE195123T1/de active
- 1996-03-22 DE DE69609602T patent/DE69609602T2/de not_active Expired - Lifetime
- 1996-03-22 CA CA002214086A patent/CA2214086C/en not_active Expired - Fee Related
- 1996-03-22 JP JP52992996A patent/JP4249804B2/ja not_active Expired - Fee Related
- 1996-03-22 NZ NZ304859A patent/NZ304859A/xx not_active IP Right Cessation
2000
- 2000-09-15 GR GR20000402103T patent/GR3034415T3/el unknown

Also Published As

Publication number	Publication date
PT819129E (pt)	2001-01-31
JPH11502859A (ja)	1999-03-09
NZ304859A (en)	2000-01-28
DE69609602D1 (de)	2000-09-07
DE69609602T2 (de)	2001-04-12
AU5273396A (en)	1996-10-23
AU711592B2 (en)	1999-10-14
CA2214086C (en)	2008-07-29
EP0819129B1 (de)	2000-08-02
US5981533A (en)	1999-11-09
ES2150113T3 (es)	2000-11-16
CA2214086A1 (en)	1996-10-10
DK0819129T3 (da)	2000-10-23
EP0819129A1 (de)	1998-01-21
JP4249804B2 (ja)	2009-04-08
GR3034415T3 (en)	2000-12-29
WO1996031510A1 (en)	1996-10-10

Legal Events

Date	Code	Title	Description
2001-01-15	UEP	Publication of translation of european patent specification

Publication	Publication Date	Title
DE69609602D1 (de)	2000-09-07	Pyrazolderivate und verfahren zu deren herstellung
ATE212993T1 (de)	2002-02-15	Pyrolopyrimidine und verfahren zu ihrer herstellung
ATE291022T1 (de)	2005-04-15	Pyrimiderivate und verfahren zu ihrer herstellung
DE69738468D1 (de)	2008-03-06	Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
ATE208778T1 (de)	2001-11-15	Pyrazolo- 1,5a)-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung
MD1632F2 (en)	2001-03-31	Bicyclic compounds, method of inhibiting the tyrosine kinases receptors as epidermal growth factor, pharmaceutical composition, methods of preventing blastocyte implantation and treatment of mammals
ATE244719T1 (de)	2003-07-15	N-7 heterocyclyl-pyrrolo( 2,3-d)pyrimidine und ihre verwendung
ATE179420T1 (de)	1999-05-15	Pyrimido (5,4-d>pyrimidine, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE69308029D1 (de)	1997-03-20	1,2,3,5,6,7,8,8a-OCTAHYDRO-5,5,8a-TRIMETHYL-(8aBETA)-6-ISOCHINOLINAMINE-DERIVATE, IHRE HERSTELLUNG UND VERWENDUNG ALS THERAPEUTIKA
EE9900315A (et)	2000-02-15	Pürrolo[3,4-d]pürimidinooni derivaadid ja nende kasutamine ravimitena
DE69206102D1 (de)	1995-12-21	Di(2-propyl)ester von 1-fluoro-2-phosphonomethoxy-3-p-toluol-sulfonyloxypropan, deren herstellung und vervendung.
DE69112432D1 (de)	1995-09-28	Derivate von methylpiperazinoazepin, verfahren zu ihrer herstellung und verwendung.
ATE207062T1 (de)	2001-11-15	Verfahren zur herstellung von substituierten pyrimidinderivaten
DE3576155D1 (de)	1990-04-05	Diazohydroxypyrazinverbindungen, verfahren zu deren herstellung und verwendung.
DE3669151D1 (de)	1990-04-05	Verfahren zur herstellung von 2-acyl-3,4-alkoxyanilinen.
ATE68489T1 (de)	1991-11-15	Triazolylmethyl-tert.-butyl-carbinolderivate, verfahren zu ihrer herstellung und ihre verwendung als planzenwachstumsregulatoren.
ATE36337T1 (de)	1988-08-15	Ethyl-benzylphosphinat-derivate, verfahren zu ihrer herstellung und ihre verwendung als calcium-antagonisten.
DE3667464D1 (de)	1990-01-18	Verfahren zur herstellung von 2-acyl-3,4-dialkoxyanilinen.
MX9606166A (es)	1998-01-31	Pirazoles substituidos.